Oshima Sonoko, Kim Asher, Sun Xiaonan R, Rifi Ziad, Cross Katy A, Fu Katherine A, Salamon Noriko, Ellingson Benjamin M, Bari Ausaf A, Yao Jingwen
From the UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers (S.O., A.K., B.M.E., J.Y.), University of California, Los Angeles, Los Angeles, California.
Department of Radiological Sciences (S.O., N.S., B.M.E., J.Y.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
AJNR Am J Neuroradiol. 2025 Feb 3;46(2):330-340. doi: 10.3174/ajnr.A8448.
Precise and individualized targeting of the ventral intermediate thalamic nucleus for the MR-guided focused ultrasound is crucial for enhancing treatment efficacy and avoiding undesirable side effects. In this study, we tested the hypothesis that the spatial relationships between Thalamus Optimized Multi Atlas Segmentation derived segmentations and the post-focused ultrasound lesion can predict post-operative side effects in patients treated with MR-guided focused ultrasound.
We retrospectively analyzed 30 patients (essential tremor, n = 26; tremor-dominant Parkinson's disease, n = 4) who underwent unilateral ventral intermediate thalamic nucleus focused ultrasound treatment. We created ROIs of coordinate-based indirect treatment target, focused ultrasound-induced lesion, and thalamus and ventral intermediate thalamic nucleus segmentations. We extracted imaging features including 1) focused ultrasound-induced lesion volumes, 2) overlap between lesions and thalamus and ventral intermediate thalamic nucleus segmentations, 3) distance between lesions and ventral intermediate thalamic nucleus segmentation and 4) distance between lesions and the indirect standard target. These imaging features were compared between patients with and without post-operative gait/balance side effects using Wilcoxon rank-sum test. Multivariate prediction models of side effects based on the imaging features were evaluated using the receiver operating characteristic analyses.
Patients with self-reported gait/balance side effects had a significantly larger extent of focused ultrasound-induced edema, a smaller fraction of the lesion within the ventral intermediate thalamic nucleus segmentation, a larger fraction of the off-target lesion outside the thalamus segmentation, a more inferior centroid of the lesion from the ventral intermediate thalamic nucleus segmentation, and a larger distance between the centroid of the lesion and ventral intermediate thalamic nucleus segmentation ( < 0.05). Similar results were found for exam-based side effects. Multivariate regression models based on the imaging features achieved areas under the curve of 0.99 (95% CI: 0.88 to 1.00) and 0.96 (95% CI: 0.73 to 1.00) for predicting self-reported and exam-based side effects, respectively.
Thalamus Optimized Multi Atlas Segmentation-based patient-specific segmentation of the ventral intermediate thalamic nucleus can predict post-operative side effects, which has implications for aiding the direct targeting of MR-guided focused ultrasound and reducing side effects.
在磁共振引导聚焦超声治疗中,精确且个体化地靶向丘脑腹中间核对于提高治疗效果和避免不良副作用至关重要。在本研究中,我们检验了以下假设:基于丘脑优化多图谱分割得到的分割结果与聚焦超声治疗后病灶之间的空间关系能够预测接受磁共振引导聚焦超声治疗患者的术后副作用。
我们回顾性分析了30例接受单侧丘脑腹中间核聚焦超声治疗的患者(特发性震颤26例;震颤为主型帕金森病4例)。我们创建了基于坐标的间接治疗靶点、聚焦超声诱导病灶以及丘脑和丘脑腹中间核分割的感兴趣区。我们提取了成像特征,包括:1)聚焦超声诱导病灶体积;2)病灶与丘脑和丘脑腹中间核分割的重叠情况;3)病灶与丘脑腹中间核分割的距离;4)病灶与间接标准靶点的距离。使用Wilcoxon秩和检验比较有和没有术后步态/平衡副作用患者的这些成像特征。基于成像特征的副作用多变量预测模型使用受试者工作特征分析进行评估。
自我报告有步态/平衡副作用的患者,其聚焦超声诱导水肿范围显著更大,丘脑腹中间核分割内病灶所占比例更小,丘脑分割外的脱靶病灶所占比例更大,病灶距丘脑腹中间核分割的质心更低,病灶质心与丘脑腹中间核分割之间的距离更大(P<0.05)。基于检查的副作用也得到了类似结果。基于成像特征的多变量回归模型预测自我报告和基于检查的副作用时,曲线下面积分别为0.99(95%CI:0.88至1.00)和0.96(95%CI:0.73至1.00)。
基于丘脑优化多图谱分割的丘脑腹中间核患者特异性分割能够预测术后副作用,这对于辅助磁共振引导聚焦超声的直接靶向和减少副作用具有重要意义。